Clinical trials recruiting for Triple Negative Breast Cancer (TNBC)
35
Recruiting trials
28
US states with sites
10
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 4 |
| Carboplatin | 3 |
| 9MW2821 | 2 |
| Famitinib | 2 |
| Letrozole | 2 |
| Nab-paclitaxel | 2 |
| Olaparib | 2 |
| Paclitaxel | 2 |
| SHR-A1811 | 2 |
| SHR-A1921 | 2 |
| 68Ga-DFC413 | 1 |
| 68Ga-NNS309 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 9 |
| California | 7 |
| Michigan | 5 |
| New York | 5 |
| Utah | 5 |
| Florida | 4 |
| Missouri | 4 |
| North Carolina | 4 |
| Colorado | 3 |
| Massachusetts | 3 |
| Ohio | 3 |
| Tennessee | 3 |
Top cities
Houston, Texas 6Duarte, California 4Grand Rapids, Michigan 4Los Angeles, California 4St Louis, Missouri 4Boston, Massachusetts 3Chapel Hill, North Carolina 3Dallas, Texas 3Nashville, Tennessee 3New York, New York 3
Self-screener
Recruiting trials
- A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
- A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
- A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
- A Study of NX-1607 in Adults With Advanced Malignancies
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
- All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
- Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
- BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
- Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
- Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of XB010 in Subjects With Solid Tumors
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- The Optimal Radioimmunotherapy Combinations for Advanced TNBC
- a Single-arm, Single-center, Open Clinical Study
Related conditions
Trials recruiting for Triple Negative Breast Cancer (TNBC) often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Colorectal cancer 1359Pancreatic cancer 870Non-small cell lung cancer 507Gastric cancer 91Prostate cancer 1234HER2-positive breast cancer 75Head and Neck Squamous Cell Carcinoma (HNSCC) 11Small Cell Lung Cancer (SCLC) 29
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Triple Negative Breast Cancer (TNBC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.